Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Status der Studie

» Solide Tumore und Neoplasien » Verschiedene solide Tumore/Neoplasien

Alle Linien

Phase I/II Studie zu AFM24 als Zweitlinientherapie bei Soliden Tumoren (Aktiv)

AMG 510_20170543
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreak 100) (Aktiv)

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug (Aktiv)

BI 907828
This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) (Aktiv)

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 (Aktiv)

Tumordiagnostische Präzisionsimmunoonkologie und somatisches Targeting rational rational for you (TAPISTRY) Phase II - Plattformversuch (Aktiv)

A Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (Aktiv)

Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients (Aktiv)

Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments (Aktiv)

First-in-human (FIH) study of DRP-104 as single agent and in combination with atezolizumab in patients with advanced solid tumors. (Aktiv)

Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients (Aktiv)

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation (Aktiv)

Magnetic Resonance-guided Adaptive Stereotactic Body Radiotherapy for Hepatic Metastases (Aktiv)

This is a phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors with known progression alone and in combination with systemic IV administration of pembrolizumab, in subjects with non-HCC liver metastases from BC, CRC, GEC, melanoma, NSCLC, RCC, and subjects with HCC. (Aktiv)

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (Aktiv)

MR Linac
Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac (Aktiv)

Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors
Master Protocol to Assess the Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors (Aktiv)

Neoadjuvante Strahlentherapie (N-RT) zur Behandlung von intrazerebalen Metastasen solider Tumore (Aktiv)

RandOmized Study Exploring the Combination of radioTherapy With Two Types of Acupuncture Treatment: The ROSETTA Trial (ROSETTA) (Aktiv)

Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost (SPIN-MET) (Aktiv)

Whole-brain radiotherapy (WBRT) versus stereotactic radiosurgery (SRS) in patients with 4 - 10 brain metastases. A phase II prospective monocentric study (Aktiv)

A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors (Aktiv)

Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside) (Aktiv)


Keynote-158, MK3475-158
Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (Aktiv)

A Phase II, single-arm trial of addition of Atezolizumab to standard chemotherapy of Platinum and Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (Aktiv)

NOA-26 - IT-PD1
Intrathekale Anwendung von PD1-Antikörpern bei metastasierten soliden Tumoren mit leptomeningealer Erkrankung (Aktiv)

Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease (Aktiv)

Zweitlinie oder später

A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours (Aktiv)

Phase I/II Studie zu AFM24 als Zweitlinientherapie bei Soliden Tumoren (Aktiv)

Amgen 20210023
Eine Phase-1/1b/2-Studie zur Bewertung der Sicherheit, Verträglichkeit, Pharmakokinetik, Pharmakodynamik und Wirksamkeit von AMG 193 allein und in Kombination mit Docetaxel bei Patienten mit fortgeschrittenen soliden MTAP-null-Tumoren (Aktiv)

BMS CA052-002
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors (Aktiv)

BMS CA224-020
The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. (Aktiv)

A Trial to Evaluate the Safety and Efficacy of CLDN6 CAR-T +/- CLDN6 RNA-LPX (Aktiv)

Bayer AhRi BAY 2416964
A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer (Aktiv)

BoB Module 1
A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (Aktiv)

An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread (Aktiv)

Phase I/II Studie zu CB-103 bei fortgeschrittenen Krebserkrankungen (Aktiv)

Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base (HIT-1) (Aktiv)

Study to allow patients with cMET-dependent malignancies to continue capmatinib treatment as monotherapy or in combination treatment (Aktiv)

study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of ALK (Aktiv)

Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab (Aktiv)

CRAFT Studie (PMO-1602)
The NCT-PMO-1602 Phase II Trial (Aktiv)

CatalYm CTL-002-001
First-in-Human Study of the GDF-15 Neutralizing Antibody CTL-002 in Patients With Advanced Cancer (GDFATHER) (Aktiv)

CheckMate 848
Nivolumab in Combination with Ipilimumab or Nivolumab Monotherapy in Advanced or Metastatic Solid Tumors (Aktiv)

A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3). (Aktiv)

I3Y-MC-JPCS Abemaciclib
A Study of Abemaciclib (LY2835219) in Combination With Temozolomide and Irinotecan and Abemaciclib in Combination With Temozolomide in Children and Young Adult Participants With Solid Tumors (Aktiv)

ICT01-102 (EVICTION-2)
A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced solid tumors. (EVICTION-2) (Aktiv)

IMA 201-101
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) (Aktiv)

IMA 401-101
A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients With Recurrent and/or Refractory Solid Tumors. (Aktiv)

INFORM2-NivEnt (NCT-2017-0516)
INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (Aktiv)

Phase I study to evaluate the feasibility and safety of IMP321 in solid tumors (Aktiv)

Radiotherapy With Integrated-boost in Patients With Spinal Bone Metastases (Aktiv)

Imcheck ICT01-101 (EVICTION)
First-in-Human Study of ICT01 in Patients With Advanced Cancer (Aktiv)

Immatics IMA 203-101
TCR-engineered T Cells in Solid Tumors (Aktiv)

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (Aktiv)

Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) (Aktiv)

Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3. (Aktiv)

A Phase 1/2 Clinical Trial of Pediatric Cancer Patients With Solid Tumors Treated with LOXO-101 (Aktiv)

Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies (Aktiv)

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (Aktiv)

Study of Pembrolizumab (MK-3475) in Children (Aktiv)

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (Aktiv)

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (Aktiv)

Evaluation of the efficacy of the combination of olaparib and trabectedin in adult patients with locally advanced/metastatic solid tumors that failed standard treatment and whose molecular sequencing tumor profiles show homologous recombination repair (HRR) defects. The primary objective is to show superior disease control rate in patients with HRR-deficient tumors treated with olaparib and trabectedin compared to treatment according to current guidelines (physician's choice) (Aktiv)

Afatinib in Advanced NRG1-Rearranged Malignancies: the NCT/DKTK PMO-1604 Phase-II Trial (Aktiv)

Novartis CDKY709A12101C
This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC (Aktiv)

PH-IL12L19L19-01/19 -Dodekin
Safety and Early Signs of Efficacy of IL12-L19L19. (Aktiv)

CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma (NCT-PMO-1601) (Aktiv)

Protonentherapie bei Kindern: Prospektive Erfassung von Effizienz und Nebenwirkungen bei klinischen Standarddosen (Aktiv)

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (Aktiv)

Hypofractionated stereotactic radiotherapy versus single fraction stereotactic radiotherapy to the resection cavity of brain metastases after surgical resection. (Aktiv)

Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)

A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (Aktiv)

Short-term Starvation vs. Normal Diet before Chemotherapy of Solid Tumors (Aktiv)

Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial (Aktiv)

TKnife TK-8001
A Phase 1/2, First-in-Human, Open-Label, Two Part Clinical Trial of TK-8001 (MAGE-A1--Directed TCR Transduced Autologous CD8+ T-cells) in Patients With HLA-A*02:01 Genotype and Advanced Stage/Metastatic, MAGE-A1+ Solid Tumors That Either Have No Further Approved Therapeutic Alternative(s) or Are in a Non-Curable State and Have Received a Minimum of Two Lines of Systemic Therapy (Aktiv)

VB N-02
Study of VB10.NEO in Combination With Atezolizumab in Solid Tumors (Aktiv)

Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit |